The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis
Open Access
- 11 May 2013
- journal article
- Published by Springer Science and Business Media LLC in Clinical Sarcoma Research
- Vol. 3 (1), 7
- https://doi.org/10.1186/2045-3329-3-7
Abstract
Background Patients with advanced solitary fibrous tumors (SFTs) have a poor prognosis; treatment options for recurrent disease are particularly limited. Several novel targeted agents have recently shown promise against advanced SFTs, but the relative efficacy of new agents is difficult to assess because data on the efficacy of conventional chemotherapy for SFTs are limited. We thus sought to estimate the efficacy of conventional chemotherapy for SFTs by reviewing data on tumor response to therapy and progression-free survival from SFT patients who received this therapy. Methods We retrospectively analyzed the clinical outcomes of 21 patients with grossly measurable, advanced SFTs (unresectable metastatic disease or potentially resectable primary tumors) who received conventional chemotherapy and follow-up at The University of Texas MD Anderson Cancer Center between January 1994 and June 2007. Best tumor response to therapy was assessed using the Response Evaluation Criteria In Solid Tumors 1.1. The Kaplan-Meier method was used to estimate median progression-free survival (PFS) duration. Results Of 21 patients, 4 received more than 1 regimen of chemotherapy, for a total of 25 treatments. Doxorubicin-based chemotherapy was given in 15 cases (60%), gemcitabine-based therapy in 5 cases (20%), and paclitaxel in 5 cases (20%). First-line chemotherapy was delivered in 18 cases (72%). No patients had a complete or partial response, 16 (89%) had stable disease, and 2 (11%) had disease progression. Five patients (28%) maintained stable disease for at least 6 months after first-line treatment. The median PFS duration was 4.6 months. The median overall survival from diagnosis was 10.3 years. Conclusion Conventional chemotherapy is effective in controlling or stabilizing locally advanced and metastatic SFTs. Our findings can serve as a reference for tumor response and clinical outcomes in the assessment of novel treatments for SFTs.Keywords
This publication has 22 references indexed in Scilit:
- Phase 2 Southwest Oncology Group‐directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomasCancer, 2011
- Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumorCancer, 2011
- Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid TumorsClinical Cancer Research, 2011
- Sunitinib Malate and Figitumumab in Solitary Fibrous Tumor: Patterns and Molecular Bases of Tumor ResponseMolecular Cancer Therapeutics, 2010
- Solitary fibrous tumors of the pleura: Results of surgical treatment and long-term prognosisThe Journal of Thoracic and Cardiovascular Surgery, 2009
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)Journal of Clinical Oncology, 2009
- Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous TumourInvestigational New Drugs, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- We Should Desist Using RECIST, at Least in GISTJournal of Clinical Oncology, 2007
- Treatment of advanced malignant hemangiopericytoma with combination adriamycin and dtic: A report of four casesJournal of Surgical Oncology, 1983